UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Structural biology of protein tyrosine kinases

Cellular and molecular life sciences : CMLS, 2006-11, Vol.63 (22), p.2608-2625

Cowan-Jacob, S W

2006

Volltextzugriff (PDF)

Imatinib: a selective tyrosine kinase inhibitor

European journal of cancer (1990), 2002-09, Vol.38, p.S19-S27

2002

Volltextzugriff (PDF)

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

British journal of cancer, 2006-06, Vol.94 (12), p.1765-1769

2006

Volltextzugriff (PDF)

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Cancer cell, 2005-02, Vol.7 (2), p.129-141

2005

Volltextzugriff (PDF)

Novel Purine Nitrile Derived Inhibitors of the Cysteine Protease Cathepsin K

Journal of medicinal chemistry, 2004-11, Vol.47 (24), p.5833-5836

2004

Volltextzugriff (PDF)

Structures of adenylosuccinate synthetase from Triticum aestivum and Arabidopsis thaliana

Journal of molecular biology, 2000-02, Vol.296 (2), p.569-577

2000

Volltextzugriff (PDF)

The Mode of Action and the Structure of a Herbicide in Complex with its Target: Binding of Activated Hydantocidin to the Feedback Regulation Site of Adenylosuccinate Synthetase

Proceedings of the National Academy of Sciences - PNAS, 1996-09, Vol.93 (18), p.9431-9436

1996

Volltextzugriff (PDF)

Structural Basis of BFL-1 for Its Interaction with BAX and Its Anti-apoptotic Action in Mammalian and Yeast Cells

The Journal of biological chemistry, 2000-04, Vol.275 (15), p.11092-11099

2000

Volltextzugriff (PDF)

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

Cancer research (Chicago, Ill.), 2005-06, Vol.65 (11), p.4500-4505

2005

Volltextzugriff (PDF)

The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation

Structure (London), 2005-06, Vol.13 (6), p.861-871

2005

Volltextzugriff (PDF)

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

Biochimica et biophysica acta, 2005-12, Vol.1754 (1), p.3-13

2005

Volltextzugriff (PDF)

Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

British journal of cancer, 2019-07, Vol.121 (3), p.282-282

2019

Volltextzugriff (PDF)

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

Pharmacology & therapeutics (Oxford), 2002-02, Vol.93 (2), p.79-98

2002

Volltextzugriff (PDF)

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

Mini reviews in medicinal chemistry, 2004-03, Vol.4 (3), p.285-299

2004

Volltextzugriff (PDF)

Allosteric Plus Catalytic BCR-ABL1 Inhibitors Promote Durable Responses

Cancer discovery, 2017-05, Vol.7 (5), p.454-454

2017

Volltextzugriff (PDF)

Crystallization and preliminary crystallographic analysis of cabbage histidinol dehydrogenase

Acta crystallographica. Section D, Biological crystallography., 1996-11, Vol.52 (6), p.1188-1190

1996

Volltextzugriff (PDF)

Structure of rabbit-muscle glyceraldehyde-3-phosphate dehydrogenase

Acta crystallographica. Section D, Biological crystallography., 2003-12, Vol.59 (12), p.2218-2227

2003

Volltextzugriff (PDF)

Novel Approaches for Targeting Kinases: Allosteric Inhibition, Allosteric Activation and Pseudokinases

Future medicinal chemistry, 2014-04, Vol.6 (5), p.541-561

2014

Volltextzugriff (PDF)

An Enzyme-Bound Bisubstrate Hybrid Inhibitor of Adenylosuccinate Synthetase

Angewandte Chemie International Edition, 1999-11, Vol.38 (21), p.3159-3162

1999

Volltextzugriff (PDF)

Structural studies of Imatinib in complex with its targets in CML and GIST: the molecular basis for selectivity and resistance

Acta crystallographica. Section A, Foundations of crystallography, 2004-08, Vol.60 (a1), p.s22-s22

Cowan-Jacob, S. W.

2004

Volltextzugriff (PDF)

STI571 (IMATINIB): structural and enzymatic studies of interactions with ABL kinase and resistance mutants

Acta crystallographica. Section A, Foundations of crystallography, 2002-08, Vol.58 (s1), p.c289-c289

2002

Volltextzugriff (PDF)

Imatinib: a selective tyrosine kinase inhibitor

European journal of cancer. Supplement (1990), 2002, Vol.38 (5), p.S19-S27

2002

Volltextzugriff (PDF)

Ten things you should know about protein kinases: IUPHAR Review 14

British journal of pharmacology, 2015-06, Vol.172 (11), p.2675-2700

2015

Volltextzugriff (PDF)

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase

Leukemia research, 2020-11, Vol.98, p.106458, Article 106458

2020

Volltextzugriff (PDF)

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Journal of medicinal chemistry, 2018-09, Vol.61 (18), p.8120-8135

2018

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(82)

Publikationsform

Sprache

Englisch
(92)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(54)
Life Sciences & Biomedicine
(47)
Humans
(31)
Animals
(22)
Models, Molecular
(20)
Pharmacology & Pharmacy
(17)
Binding Sites
(15)
Chemistry, Medicinal
(15)
Benzamides
(14)
Biochemistry & Molecular Biology
(14)
Imatinib Mesylate
(14)
Physical Sciences
(14)
Pyrimidines - Pharmacology
(14)
Protein Kinase Inhibitors - Chemistry
(13)
Protein Kinase Inhibitors - Pharmacology
(13)
Crystallography, X-Ray
(12)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(12)
Mice
(12)
Biological And Medical Sciences
(11)
Chemistry
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Structural biology of protein tyrosine kinases

Imatinib: a selective tyrosine kinase inhibitor

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Novel Purine Nitrile Derived Inhibitors of the Cysteine Protease Cathepsin K

Structures of adenylosuccinate synthetase from Triticum aestivum and Arabidopsis thaliana

The Mode of Action and the Structure of a Herbicide in Complex with its Target: Binding of Activated Hydantocidin to the Feedback Regulation Site of Adenylosuccinate Synthetase

Structural Basis of BFL-1 for Its Interaction with BAX and Its Anti-apoptotic Action in Mammalian and Yeast Cells

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

Allosteric Plus Catalytic BCR-ABL1 Inhibitors Promote Durable Responses

Crystallization and preliminary crystallographic analysis of cabbage histidinol dehydrogenase

Structure of rabbit-muscle glyceraldehyde-3-phosphate dehydrogenase

Novel Approaches for Targeting Kinases: Allosteric Inhibition, Allosteric Activation and Pseudokinases

An Enzyme-Bound Bisubstrate Hybrid Inhibitor of Adenylosuccinate Synthetase

Structural studies of Imatinib in complex with its targets in CML and GIST: the molecular basis for selectivity and resistance

STI571 (IMATINIB): structural and enzymatic studies of interactions with ABL kinase and resistance mutants

Imatinib: a selective tyrosine kinase inhibitor

Ten things you should know about protein kinases: IUPHAR Review 14

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Suchergebnisse filtern